(Q61975909)
Statements
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis (English)
0 references
October 2013
0 references
March 2015
0 references
255
0 references
18 year
0 references
60 year
0 references